Arcutis biotherapeutics stock.

Since the trade, Arcutis Biotherapeutics Inc's stock has declined by 20.89%, and it has plummeted by 91.54% since its IPO. The year-to-date performance is also down by 86.8%. With no applicable GF ...These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...About Arcutis Biotherapeutics Inc. Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical ...Nov. 29, 2023, 08:24 AM. (RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT) announced the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% …

Arcutis Biotherapeutics last posted its earnings data on November 3rd, 2023. The reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.17. The firm earned $38.11 million during the quarter, compared to the consensus estimate of $9.54 million. Arcutis Biotherapeutics has generated ($4. ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing …Latest News. November 15, 2022. Get Arcutis Biotherapeutics Inc (ARQT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.

One company hoping for such success is Arcutis Biotherapeutics (ARQT 4.08%). It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff ...

Based on 6 Wall Street analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $9.60 with a high ...About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in …In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. Morgan Stanley, Cowen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.Sep 25, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17 with a high of $57.00 and a low of $22.00. Nov 9, 2023 · Arcutis Biotherapeutics (NASDAQ:ARQT) Third Quarter 2023 ResultsKey Financial Results. Revenue: US$38.1m (up by US$37.4m from 3Q 2022). Net loss: US$44.8m (loss narrowed by 58% from 3Q 2022).

In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of Arcutis’ common stock at the public offering price less the underwriting discounts and commissions. ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and ...

Dec 1, 2023

Earlier this month, the company added to its pipeline assets by acquiring privately held Ducentis Biotherapeutics for an upfront cash payment of ~$16 million and Arcutis stock valued at ~$14 ...Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Sep 25, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17 with a high of $57.00 and a low of $22.00. Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $44.00. The associated price target is ...Review Arcutis Biotherapeutics Inc Ordinary Shares (ARQT:XNAS) stock's current information regarding return on assets, equity, invested capital, margins, and turnover over the last fiscal year.

The last twelve months weren't great for Arcutis Biotherapeutics shares, which cost holders 60%, while the market was up about 6.6%. However, keep in mind that even the best stocks will sometimes ...WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for ...About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis …Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » ARQT Arcutis …Nov 15, 2023 · Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...Stock Price, News, Quote and Profile of ARCUTIS BIOTHERAPEUTICS INC(NASDAQ:ARQT) stock. General stock ratings, overview and activity description.Arcutis Biotherapeutics, Inc. (ARQT) Stock Price | Stock Quote Nasdaq - MarketScreener ARCUTIS BIOTHERAPEUTICS, INC. Equities ARQT US03969K1088 Biotechnology & …Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Alkermes, and Relmada Therapeutics. According to TipRanks , Ear has an average return of -1.6% and a 23.68% ...Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($3.78) to ($2.65) per share. Arcutis Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.What this means: InvestorsObserver gives Arcutis Biotherapeutics Inc (ARQT) an overall rank of 33, which is below average. Arcutis Biotherapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.Dec 1, 2023 · Arcutis Biotherapeutics stock has received a consensus rating of buy. The average rating score is and is based on 30 buy ratings, 2 hold ratings, and 0 sell ratings. What was the 52-week low for ...

As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ...

The Investor Relations website contains information about Arcutis Biotherapeutics's business for stockholders, potential investors, and financial analysts.

Nov 24, 2023 · A high-level overview of Arcutis Biotherapeutics, Inc. (ARQT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Arcutis Biotherapeutics (NASDAQ:ARQT) has observed the following analyst ratings within the last quarter: These 6 analysts have an average price target of $34.83 versus the current price of ...Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported, And Analysts Assigned A US$41.57 Price Target. (Simply Wall St.) Aug-10-23 08:16AM. Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia. (GlobeNewswire) Aug-09-23 09:23AM.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ...Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 7.83 years. total yearly compensation is $4.58M, comprised of 12.9% salary and 87.1% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $798.75K. The average tenure of the management team and the board of ...WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for …Find the latest Arcutis Biotherapeutics, Inc. (ARQT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Nov 8, 2022 · The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. Arcutis Biotherapeutics, Inc. Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter ...

WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2022, and provided a business update. ...Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.Arcutis Biotherapeutics stock has received a consensus rating of buy. The average rating score is and is based on 30 buy ratings, 2 hold ratings, and 0 sell ratings. What was the 52-week low for ...Instagram:https://instagram. prmsxtradelog alternativesoptionstrat reviewsafest place to buy silver online In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics ( ARQT – Research Report ), with a price target of $57.00. The company’s shares ... best suv ever madebab astock Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. best financial advisors scottsdale Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Real time Arcutis Biotherapeutics (ARQT) stock price quote, stock graph, news & analysis.